Neuropsychiatric Events Associated with Leukotriene-Modifying Agents: A Systematic Review. by Law, Sharon WY et al.
LSHTM Research Online
Law, Sharon WY; Wong, Angel YS; Anand, Shweta; Wong, Ian CK; Chan, Esther W; (2018) Neu-
ropsychiatric Events Associated with Leukotriene-Modifying Agents: A Systematic Review. Drug
safety, 41 (3). pp. 253-265. ISSN 0114-5916 DOI: https://doi.org/10.1007/s40264-017-0607-1
Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/4655330/
DOI: https://doi.org/10.1007/s40264-017-0607-1
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
https://researchonline.lshtm.ac.uk
0 
 
Full Title: Neuropsychiatric Events Associated with Leukotriene-modifying Agents: A 
Systematic Review 
Running Title: Neuropsychiatric Events Associated with Leukotriene-modifying Agents 
Sharon W. Y. Law1, Angel Y. S. Wong1, Shweta Anand1, Ian C. K. Wong1,2, Esther W. Chan1 
 
Affiliations 
1Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing 
Faculty of Medicine, The University of Hong Kong, Office 02-08, 2/F Laboratory Block, 21 Sassoon Road,  
Hong Kong SAR, China 
2Research Department of Practice and Policy, School of Pharmacy, University College London, 29-39 
Brunswick Square, London WC1N 1AX, United Kingdom 
 
Corresponding Author  
Esther W. Chan  
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy,  
Li Ka Shing Faculty of Medicine, The University of Hong Kong,  
Office 02-08, 2/F Laboratory Block, 21 Sassoon Road,  
Hong Kong SAR, China 
Email: ewchan@hku.hk 
Telephone: +852 2831 5110 
 
Acknowledgements 
We thank Joseph E. Blais (Centre for Safe Medication Practice and Research) for proofreading the manuscript.  
1 
 
Abstract  
Introduction Leukotriene-modifying agents (LTMAs) including montelukast, zafirlukast, and zileuton are 
approved by the U.S. Food and Drug Administration (FDA) for the treatment of asthma and allergic rhinitis. 
Various neuropsychiatric events (NEs) have been reported; however, the evidence of the association is conflicting. 
This systematic review investigates the association between NEs and LTMAs by assessing the relevant published 
literature.  
Methods PubMed, EMBASE, MEDLINE, and Cochrane Library were searched using keywords. Studies 
designed to investigate the association were eligible for inclusion without restriction to any study design or 
language. The primary outcome was defined as suicidal conditions while secondary outcomes included all other 
NEs.  
Results Thirty-three studies were included for a narrative review. Four observational studies did not find a 
significant association while 10 pharmacovigilance studies using different global databases detected the signals. 
Notably, some studies suggest that the FDA warning issued in 2008 might have influenced the reporting rate of 
NEs due to increased awareness.  
Limitations The risk of NEs was not quantified due to the lack of randomized controlled trials and observational 
studies investigating the association. 
Conclusion Many pharmacovigilance studies have been conducted to determine the association between NEs and 
LTMAs but there is limited evidence from observational studies. High quality epidemiological studies should be 
conducted to evaluate the association and quantify the risk, not only in children but also in adults. 
 
Key Points 
 Observational studies did not find a significant association between neuropsychiatric evnets (NEs) and 
leukotriene-modifying agents (LTMAs).  
 Many pharmacovigilance studies detected the signal of NEs during LTMA treatment.   
 The warning issued by the U.S. Food and Drug Administration might have influenced the reporting rate 
of NEs. 
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1 Introduction 
Montelukast, zafirlukast, and zileuton are leukotriene-modifying agents (LTMAs) approved by the U.S. Food and 
Drug Administration (FDA) in late 1990s for the prophylaxis and chronic treatment of asthma [1-3]. Montelukast 
is further indicated for the prevention of exercise-induced bronchoconstriction and relief of symptoms of allergic 
rhinitis and it can be used in children as young as 6 months for the latter indication [3]. With the once-daily dosing 
regimen, ease of administration and good safety profile, montelukast is the most widely prescribed LTMA. 
However, various neuropsychiatric events (NEs) have been reported with the use of LTMAs over the past two 
decades [4-13].  
Based on the results of post-marketing pharmacovigilance studies, the FDA issued a warning about the association 
and alerted the healthcare professionals in 2008 [14]. NEs including agitation, aggressive behavior or hostility, 
anxiousness, depression, disorientation, disturbance in attention, dream abnormalities, hallucinations, insomnia, 
irritability, memory impairment, restlessness, somnambulism, suicidal ideation and behavior (including suicide), 
and tremor were added to the package labels of LTMAs more than ten years after the medications were launched 
[1-3, 14]. Nonetheless, the concerns about the neuropsychiatric safety of LTMAs in children was raised again 
recently due to cases reported in the Australian media [15]. Parents complained that they were not warned of the 
possible association when they received the medications [15]. However, the evidence of the association between 
NEs and LTMAs has been conflicting and the risk has not been quantified in previous studies [16-20].  
Literature reviews and analyses were conducted based on the results of randomized controlled trials (RCTs) [16-
19]; however, NEs are rare outcomes and they are difficult to detect in RCTs that have a short follow-up and 
relatively small sample size. Observational studies could complement the findings of RCTs since they have greater 
generalisability and longer follow-up time. With the concerns about the neuropsychiatric safety of LTMAs, some 
observational and pharmacovigilance studies were conducted to examine this association [4-13, 21-24]. This 
review aims to systematically evaluate the evidence from the published literature of different study designs to 
investigate the association between NEs and LTMAs. 
2 Method 
2.1 Search Strategy 
This systematic review was conducted according to the study protocol that is available on the website of the Centre 
for Safe Medication Practice and Research (http://www.pharma.hku.hk/sweb/CSMPR/). Four databases, 
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including PubMed, EMBASE, MEDLINE, and Cochrane Library, were searched on 16 November, 2016 to locate 
relevant literature using keywords, MeSH, and Emtree which are related to the drugs of interest and various NEs. 
The bibliography of the retrieved articles was manually screened to further expand the search for study inclusion. 
The detailed search strategy for each database is shown in supplementary material 1.  
2.2 Inclusion and Exclusion Criteria 
All published studies which were designed to investigate the association between NEs and LTMAs were eligible 
for selection without restriction to any study design or language. Online translation tools were used if the article 
was written in a language other than Chinese or English. To assess for publication bias, conference abstracts were 
considered to be eligible in this review. The population of interest were patients of all ages who were exposed to 
any LTMA for any indication. Animal studies were excluded. In addition, we excluded the older studies if more 
than one studies with the same data source, study period, and outcomes of interest were identified. 
2.3 Data Collection 
Citations and abstracts of the search results were stored in Endnote X7 for evaluation and selection. To reduce 
selection bias, all titles and abstracts were screened by two independent reviewers (SWYL, AYSW) according to 
the eligibility criteria. Any discrepancy was resolved by consensus. PICO items including the data source of the 
study, type of study design, demographics of participants, intervention (specific LTMA used, dose and duration 
of treatment), outcomes of interest (neuropsychiatric events), follow-up time, sample size, and covariates for 
adjustment were extracted and compiled in a data extraction form.  
Due to the clinical importance, the primary outcome of interest was defined as suicidal conditions, including 
completed suicide, suicide attempt, suicidal ideation, and self-harm either presented separately or as a combined 
outcome. The rare occurance of suicidal conditions was evaluated as a separate outcome. Secondary outcomes 
included other NEs such as hallucinations, psychosis, personality disorders, agitation, hostility, irritability, 
depression, anxiety, mood disorders, hyperactivity, cognitive impairment, sleep disorders, dream abnormalities, 
seizure, and tremor to further inform the overall neuropsychiatric safety profile of LTMAs. 
2.4 Quality Assessment 
The quality of the included studies was assessed independently by two reviewers (SWYL, AYSW). The 
Newcastle-Ottawa scale was used to assess the methodology of the included observational studies. Due to the lack 
of standard assessment tools for interrupted time series (ITS) analysis, pharmacovigilance studies, case series, and 
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case reports, these findings were narratively described. The quality of the studies from conference abstracts was 
not assessed in this review as information on methods was limited.  
3 Results 
3.1 Search Results  
Thirty-three studies, including two non-English studies [12, 25], were selected for a narrative review. The study 
types include cohort studies (n = 2) [21, 23], nested case-control studies (n = 2) [22, 24], pharmacovigilance 
studies (n = 10) [4-13], ITS analysis (n = 2) [26, 27], case series (n = 1) [28], case reports (n = 6) [29-34], review 
of case reports (n = 1) [25], and conference abstracts (n = 9) [35-43]. Of the included articles, twelve studies 
reported suicidal conditions as one of the outcomes [6, 10, 11, 21-23, 25, 26, 32, 36, 37, 40]. The PRISMA flow 
diagram of the review is shown in Fig. 1.  
3.2 Methodological Quality of Observational Studies 
For methodological quality, one cohort study scored relatively high as the selection of cohort demonstrated 
representativeness [23]. However, only a subgroup analysis was performed regarding montelukast and the 
comparison was based on the cumulative defined daily dose but not between exposed and unexposed groups. 
Adjustment was made in accordance with the possible confounders but the severity of asthma was not considered. 
The outcome was assessed adequately but the loss of follow-up was not reported [23]. Jick et al. resulted in a low 
score as they did not demonstrate a high quality of cohort selection, comparability, and outcome measurement 
[21]. The follow-up period was not specified and no appropriate unexposed group was used for risk comparison 
[21].  
The overall quality of two nested case-control studies [22, 24] was high in terms of the sample selection, 
comparability, and exposure. Adequate adjustment for the covariates was made in both studies with Ali et al. [24] 
adjusting the analysis for socioeconomic status overcoming the limitation identified in Schumock et al. study [22]. 
Quality assessment results are presented in supplementary material 7 and 8. 
3.3 NEs Associated with LTMAs 
Owing to the heterogeneity of different study designs, the results could not be pooled in a meta-analysis. Two 
nested case-control studies were identified but they originated from the same data source [22, 24]; therefore, meta-
analysis was not conducted. This narrative review is structured based on study designs and outcomes. Table 1 and 
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2 summarize the characteristics of the included analytic studies and pharmacovigilance studies respectively while 
supplementary material 2 to 6 summarize the case series, case reports, reviews, and conference abstracts. 
3.3.1 Observational Studies 
Regarding the primary outcome, two cohort studies did not find a significant association between montelukast 
and suicidal conditions [21, 23]. One case of suicide in Jick et al. cohort occurred two years after a short course 
of (28 days) montelukast and was not considered to be related to the medication exposure [21]. The lack of 
outcome occurrence may be due to rare events, inadequate sample size and a short follow-up period. Chen et al. 
investigated the association between asthma and self-harm instead of the association with LTMAs [23]. However, 
the association between self-harm and montelukast was assessed in the subgroup analysis by the cumulative 
defined daily dose. No increased risk of self-harm was found (adjusted hazard ratio [HR] 0.92, 95% confidence 
interval [CI] 0.29–2.91) for the higher dose versus the lower dose [23]. Of note, cases of completed suicide were 
excluded from the study cohort with only self-harm included as the outcome [23].  
Two nested case-control studies from the same data source were identified but only Schumock et al. investigated 
the association between suicide attempt and LTMAs [22, 24]. The adjusted odds ratio (OR) was 0.70 (95% CI 
0.36–1.39) which showed a potential risk reduction but the results were not statistically significant [22]. On the 
contrary, a stratified analysis for the 19 to 24-year age group showed an increased risk but the CI was wide 
(adjusted OR 5.15, 95% CI 1.16–22.86) [22]. Notably, the study focused on asthmatic children and young adults 
only. The results were also mainly driven by montelukast due to its frequent use in clinical practice when 
compared to other LTMAs, with 233 over 238 subjects on montelukast in the study [22].  
For the secondary outcomes, only one observational study evaluated the composite of NEs associated with 
montelukast in children with asthma [24]. Subgroup analyses were conducted based on the cumulative dose, 
treatment duration, and recency of exposure. The adjusted OR for any exposure to montelukast in the past year 
was 1.01 (95% CI 0.88–1.14) [24]. Post hoc analyses were conducted for different types of NEs. Among all cases, 
adjustment disorders (adjusted OR 1.34, 95% CI 0.99–1.79) were the most commonly seen NEs, followed by 
attention deficit disorder/attention deficit hyperactivity disorder (adjusted OR 1.07, 95% CI 0.80–1.44) [24]. No 
consistent significant positive association was found in the study. 
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3.3.2 Interrupted Time Series Analysis  
Two studies using ITS analysis were included in this review [26, 27]. Zhou et al. used the dispensing records of 
antidepressants as a surrogate for NEs [27]. They found a significant increase in the dispensing rate of 
antidepressants in patients aged between 18 and 24 years after starting montelukast [27]. However, the effect was 
also found to be statistically significant in the comparison groups which included fluticasone and long-acting beta-
agonist with inhaled corticosteroid (LABA/ICS). The authors concluded that NEs were not associated with the 
use of montelukast [27].  
The change in the reporting rate of NEs before and after the FDA warning was investigated in the other ITS 
analysis conducted by Lu et al. [26]. They found an increase in mental health visits among adolescents and adults 
after the FDA warning was issued [26]. An increase in suicide attempts was also detected among young adults 
[26]. In light of these findings, it was suggested that the FDA warning may have raised awareness and increased 
the reporting of mental health symptoms [26].  
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Table 1 Study characteristics of analytic studies 
Study Study 
design 
Region Data 
source 
Study 
period 
Inclusion criteria Exclusion criteria Exposure Number of 
subjects 
Follow-
up  
Covariates Results and outcomes of interest 
Jick et al. 
[21] 
Cohort United 
Kingdom 
GPRD  Feb 1998–
Mar 2007 
≥1 prescriptions of M --- M 23500 
No unexposed 
group 
 
--- --- Rate of suicide  
Number of suicides in 21050 person-years at 
risk = 0 
Chen et 
al. [23] 
Cohort Taiwan National 
Health 
Insurance 
Research 
Database  
2000–2008 Aged >10 years with 
inpatient diagnosis 
and/or ≥2 recorded 
diagnoses and 1 year 
duration of asthma in 
outpatient setting 
 
Completed suicide 
(Deaths within 2 weeks 
of self-harm) 
M cDDD 0–90: 
726 
cDDD ≥90: 
165960 
Mean: 
5.84 
years 
Age, sex, area of residence, 
insurance premium, 
episode of psychiatric 
disease, M and  
Charlson comorbidity 
index 
Self-harm 
Adjusted HRa = 0.92 (95% CI 0.29–2.91) 
Schumock 
et al.  [22] 
Nested 
case-
control 
United 
States 
LifeLink 
Health Plan 
Claims 
Database 
1997–2006 Aged 5–24 years with 
≥1 prescriptions of an 
asthma  controller 
medication 
Index date ≥30 days 
before asthma diagnosis, 
last enrolment date 
≤index date, not 
continuously enrolled for 
≥6 months, or  
significant gaps of 
enrolment for ≥2 months 
 
LTMAs Case: 344 
Control: 3438 
180 days  Asthma severity, 
comorbidities associated 
with a higher risk of SA, 
previous SA/psychological 
counselling, and 
current/past use of 
medications with increased 
risk of suicide 
 
SA 
Adjusted OR = 0.70 (95% CI 0.36–1.39) 
Ali et al. 
[24] 
Nested 
case-
control 
United 
States 
LifeLink 
Health Plan 
Claims 
Database 
1998–2009 Aged 1–17 years with 
a primary diagnosis of 
asthma, and health 
plan and pharmacy 
benefit eligibility 12 
months before and 
after the asthma claim 
 
Developmental or 
pervasive developmental 
disorder, receiving long-
term care, or pre-existing 
NEs 365 days before 
asthma claim 
 
M Case: 1920 
Control: 5760 
365 days Asthma severity, factors 
prognostic of psychiatric 
disorders, and low socio-
economic status 
NEs 
Adjusted OR = 1.01 (95% CI 0.88–1.14) 
Zhou et 
al. [27] 
ITS United 
States 
Wolters 
Kluwer’s 
SOURCE 
Lx 
pharmacy 
claims 
database 
2003–2007 Aged ≤45 years with 
≥2 prescriptions of M 
and had ≥1 medical/ 
pharmacy claim 12 
months before and 12 
months after the index 
date 
Had other asthma 
controller medications 
12 months before and 3 
months after the index 
date 
M M: 232159 
F: 264704  
LABA/ICS: 
89635  
180 days --- Antidepressant dispensing rate after initiating 
the medication 
1) Patient aged 12–17 yearsb: 
M (0.80%, 95% CI 0.31–1.29%, p < 0.001), 
F (0.83%, 95% CI -0.08–1.73%), 
LABA/ICS (0.76%, 95% CI 0.22–1.30%, p 
< 0.05) 
2) Patients aged 18–24 years#: 
M (1.93%, 95% CI 1.55–2.32%, p < 0.001), 
F (1.72%, 95% CI 1.30–2.15%, p < 0.001), 
LABA/ICS (2.76%, 95% CI 2.35–3.17%, p 
< 0.001) 
 
Lu et al. 
[26]  
ITS United 
States 
Population-
based 
Effectivene
ss in 
Asthma and 
Lung 
Diseases 
Network 
2005–2010 Aged 5–64 years with 
≥1 outpatient or 
inpatient visit with a 
diagnosis of asthma 
and continuous 
enrolment in the past 
12 months (rolling 
cohort) 
History of COPD, cystic 
fibrosis, bronchiectasis, 
pulmonary  
hypertension/ embolism; 
bronchopulmonary 
dysplasia; or CHF in the 
past 12 months 
LTMAs 140,000 18 
months 
--- Immediate impact on MHV and SA after the 
FDA warning 
1) Patients aged 5–17 years 
MHV (0.25%, 95% CI 0.01–0.49%, p = 
0.0454); SA (0) 
2) Patients aged 18–29 years 
MHV (0); SA (0.03%, 95% CI 0.01–0.05%, 
p = 0.0032) 
3) Patients aged 30–64 years 
MHV (0.61%, 95% CI 0.30–0.91%, p = 
0.0002); SA (0)  
GPRD General Practice Research Database, M montelukast, cDDD cumulative defined daily dose, HR hazard ratio, CI confidence interval, LTMAs leukotriene-modifying agents, SA suicide attempt, OR odds ratio, NEs neuropsychiatric 
events, ITS interrupted time series, F fluticasone, LABA/ICS long-acting beta-agonist/inhaled corticosteroid, p p-value, COPD chronic obstructive pulmonary diseases, CHF congestive heart failure, MHV mental health visits. aPresented 
as the subgroup analysis by comparing the cumulative defined daily dose. bITS was performed separately for four age categories with a focus on patients aged 12–17 years and 18–24 years.
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3.3.3 Pharmacovigilance Studies 
Pharmacovigilance studies cannot quantify the risks but they can be used to detect signals, especially when rare 
adverse drug reactions (ADRs) cannot be identified in the RCTs. Ten studies investigating ADRs that implicated 
LTMA use were included [4-13]. They were conducted using different databases worldwide including the Drug 
Safety Research Unit from the United Kingdom [4, 5], the Swedish Drug Information System (SWEDIS) from 
Sweden [6, 7], the Spanish System of Pharmacovigilance from Spain [13], the Food and Drug Administration 
Adverse Event Reporting System (FAERS) from the United States [11], the French Pharmacovigilance Database 
(FPVD) from France [9, 12], the EudraVigilance (EV) from  European Union (EU) [8], and the Vigibase from the 
World Health Organization (WHO) [10]. Almost half of the studies only included patients aged less than 18 years 
[6-8, 10] and most of them focused mainly on ADRs related to montelukast [4, 6-10, 12, 13].  
The rate of suicidal conditions was investigated in three pharmacovigilance studies [6, 10, 11]. Bygdell et al. 
reported one case of suicidal condition that implicated the use of montelukast in the SWEDIS during a 10-year 
period [6]. Schumock et al. conducted another study based on the FAERS in 1999–2009 and found that 105 
completed suicides involved the use of LTMAs, with 96% of the reports relating to the use of montelukast [11]. 
The suicide rate was calculated based on the number of dispensed prescriptions. The result was compared with 
short-acting beta-agonists (SABAs), which are the first-line treatment of asthma; and selective serotonin reuptake 
inhibitors (SSRIs), which are likely associated with suicide [11]. The suicide rate for montelukast was higher than 
for SABAs but lower than for SSRIs [11]. Notably, comparing the rates before and after the warning issued by 
the FDA, the post warning rate was higher than that in the pre-warning period [11]. This finding is consistent with 
the aforementioned ITS analysis [26], which suggested that the warning may have increased the reporting rate. 
Aldea-Perona et al. reported a total of 674 ADRs of suicidal and self-injurious behavior (26% of all ADRs) 
possibly associated with montelukast from the Vigibase [10]. Suicidal conditions also predominated in adolescents 
aged between 12 to 17 years with positive de-challenge and re-challenge demonstrated in some cases [10].  
Biswas et al. detected NEs from users of montelukast and found 36 cases of insomnia, 10 cases of drowsiness and 
5 cases of depression [4]. Twaites et al. did a subsequent study using the same data source but on a different 
LTMA, zafirlukast [5]. Seventy-nine cases of depression were reported which accounted for 1% of the cohort [5]. 
However, the incidence density difference was -1.1 (99% CI, -2.4–0.3) [5]. Two pharmacovigilance studies were 
conducted based on the SWEDIS but in different study periods so both were included [6, 7]. Forty-eight and 60 
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psychiatric ADR reports of children taking montelukast were identified by Wallerstedt et al. and Bygdell et al. 
respectively [6, 7]. The main NEs were nightmares, sleep disorders, anxiety, and aggressiveness.  
Cereza et al. searched the Spanish database and retrieved 24 reports of nightmares associated with montelukast 
[13]. Concomitant psychiatric symptoms were insomnia, nervousness, hallucinations, aggressiveness, irritability, 
and anxiety [13]. Most of the patients were children aged 2 to 7 years [13]. Marchand et al. used the French 
database and found that sleep disorders, behavioral disorders, and depression were commonly reported in patients 
taking montelukast [12]. Lafay-Chebassie et al. also found four reports for depression in patients taking 
montelukast using the same database but in a slightly different study period [9].  
A total of 31 psychiatric ADRs related to the use of montelukast were identified by Aagaard et al. in the EV 
database [8]. Psychiatric events were the frequent ADRs reported for montelukast and the main symptoms were 
nightmares and aggression [8]. Interestingly, the number of reports identified in the EV database from EU was 
comparatively smaller than those reported in other studies when a nation-wide database was used over a similar 
study period. In contrast, the study conducted by Aldea-Perona et al. using the Vigibase identified a large number 
of psychiatric ADRs related to the use of montelukast (n = 2630) when they searched the database up to  1 January, 
2015 [10]. Different psychiatric symptoms were dominant in different age groups and more cases in males were 
reported. The most frequently reported psychiatric ADRs were sleep terror and nightmares.   
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Table 2 Study characteristics of pharmacovigilance studies 
Study Region  Data source Study period Inclusion criteriaa Exposure Results and outcomes of interest 
Biswas et al. [4] United 
Kingdom 
Drug Safety Research 
Unit 
 
Feb 1998–
Dec 1998 
ADRs 6 months following an 
NHS prescription of 
montelukast 
 
Montelukast 1) 250 ADRs in 191 patients (1.2% of total cohort)  
2) NEs reported: insomnia, drowsiness, abnormal dreams, depression 
 
Twaites et al. 
[5] 
United 
Kingdom 
Drug Safety Research 
Unit  
Mar 1999–
Aug 2001 
ADRs 6 months following the 
first NHS prescription of 
zafirlukast 
 
Zafirlukast 1) 152 ADRs in 120 patients (1.5% of total cohort)  
2) NEs reported: depression, anxiety, confusion, aggression, agitation  
3) Incidence density difference for depression = -1.1 (99% CI, -2.4–0.3)  
 
Wallerstadt et 
al. [7] 
Sweden Swedish Drug 
Information System  
 
1998–2007 Psychiatric ADRs in patients 
aged <18 years using 
montelukast 
 
Montelukast 1) 48 psychiatric ADRs in 103 total ADRs of montelukast 
2) 48% of the children with psychiatric ADRs were ≤3 years 
3) NEs reported: nightmares, unspecified anxiety, aggressiveness, sleep disorders, insomnia, irritability, 
hallucination, hyperactivity, personality disorder, depressed mood, impaired concentration, amnesia 
 
Bygdell et al. 
[6] 
Sweden Swedish Drug 
Information System  
2001–2010 Psychiatric ADRs in patients 
aged <18 years of all suspected 
medications 
Montelukast 1) 60 ICSRs of psychiatric ADRs of montelukast  
2) NEs reported: sleep disorder, anxiety, hyperactivity, personality disorder, aggressiveness, suicidal 
conditions 
 
Cereza et al. 
[13] 
 
Spain Spanish System of 
Pharmacovigilance 
Up to Dec 
2011 
Psychiatric ADRs focusing 
mainly on nightmares in 
patients using montelukast 
   
Montelukast 1) NEs reported: nightmares, insomnia, nervousness, hallucinations, aggressiveness, irritability, anxiety 
Schumock et al. 
[11] 
United States FDA Adverse Event 
Reporting System 
(FAERS) and Xponent 
database (IMS Health, 
Inc.) 
1999–2009 Completed suicide associated 
with LTMAs from FAERS and 
number of dispensed 
prescriptions from Xponent 
database 
 
LTMAs  
 
Comparisons: 
SSRIs and 
SABAs 
1) 105 cases of completed suicides (101 cases for montelukast) 
2) Suicide rates per million prescriptions: LTMAs = 0.50 (95% CI 0.41–0.61); SSRIs = 2.79 (95% CI 2.69–
2.90); SABAs =  0.17 (95% CI 0.14–0.21) 
3) 92 cases occurred following the FDA warning in 2008 
4) Suicide rates per million prescriptions of LTMAs: before 2008 = 0.06 (95% CI 0.01–0.10); after 2008 = 
1.82 (95% CI 1.47–2.23) 
 
Marchand et al. 
[12] 
France French 
pharmacovigilance 
database  
 
20 Mar  
1998–28 Feb  
2012 
ADRs of montelukast Montelukast 1) 56 psychiatric ADRs in 295 total ADRs of montelukast 
2) NEs reported: nightmares, insomnia, somnolence, aggressiveness, agitation, irritability, hyperactivity, 
nervousness, hallucinations, depression 
Aagaard et al. 
[8] 
European Union 
 
EudraVigilance  2007–2011 ADRs in patients <18 years 
using any asthma medications 
 
Montelukast 1) 31 psychiatric ADRs in 76 total ADRs of montelukast  
2) NEs reported: nightmares and aggression 
 
Lafay-
Chebassie et al. 
[9] 
France French 
pharmacovigilance 
database  
 
Jan 2007–
Dec 2011 
ADRs relating to depression of 
all medications 
Montelukast 1) 4 ADRs of depression in 111 total ADRs of montelukast 
2) Reporting odds ratiob = 8.9 (95% CI 3.3–24.3, p < 0.001) 
Aldea-Perona et 
al. [10] 
Worldwide VigiBase from World 
Health Organization  
 
Up to Jan 1 
2015 
Psychiatric ADRs in patients 
aged <18 years using 
montelukast  
Montelukast 1) 2630 ICSRs of psychiatric ADRs in 14670 total ICSRs of montelukast 
2) NEs reported: suicidal behavior, anxiety, changes in physical activity, cognitive and attention disorders, 
communication disorders, delirium (including confusion), depressed mood disorders, disturbances in 
thinking and perception, impulse control disorders, mood disorders, personality disorders, disturbances in 
behavior, psychiatric disorders, schizophrenia and other psychotic disorders, sleep disorders 
 
ADRs adverse drug reactions, NEs neuropsychiatric events, NHS National Health Service, CI confidence interval, ICSR individual case safety reports, FDA Food and Drug Administration, LTMAs leukotriene-modifying agents, SSRIs 
selective serotonin reuptake inhibitors, SABAs short-acting beta-agonists. aNo exclusion criteria presented in all included pharmacovigilance studies. bCase/non-case method was used.
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3.3.4 Case Series, Case Reports, and Reviews 
Six case reports were identified in our search in which all NEs were linked to the use of montelukast [29-34]. 
Only one case of suicide attempt was reported and positive de-challenge was demonstrated [32]. Other NEs 
identified in the case reports included hallucinations, anxiety, sleep disorders, nightmares, behavioral disturbances, 
aggressiveness, irritability, confusion, and attention deficit [29-34]. Delayed onset of symptoms was reported by 
Byrne et al. in which anxiety was diagnosed 2.5 years after starting the treatment [31]. Positive de-challenge was 
demonstrated in all but one case within 2 to 28 days [29-34].  
Erdem et al. conducted the study using the database at a children’s hospital and reported 41 psychiatric ADRs 
among 1024 patients using LTMAs [28]. Cheng et al. conducted a review on ADR reports related to montelukast 
by searching the Chinese National Knowledge Infrastructure (CNKI) and VIP database [25]. They found that five 
out of 18 reports were related to NEs which included psychosis, sleep disorders, irritability, suicide attempt, and 
attention deficit [25]. However, specific information of the case reports provided in the article was limited.    
3.3.5 Conference Abstracts 
Conference abstracts with different study designs were included for a comprehensive review. Three observational 
studies consisted of a relatively small sample size, ranging from 24 to 8545 subjects [38, 40, 42]. Iessa et al. did 
not find a significant association between suicide attempt and LTMAs [40]. Although Narang et al. did not find 
an association between depression and montelukast [42], Rhee et al. reported a significant increased risk of 
depression in patients taking LTMAs with a HR of 1.50 (95% CI 1.02–2.21) when compared with inhaled 
corticosteroids in a Korean cohort [38].  
Pharmacovigilance studies using databases from Spain, Italy, the United States and the WHO were conducted 
[35-37, 39]. Two cases of suicidal ideation were identified [36]. Gadde et al. investigated ADRs of montelukast 
and found that aggression was the most frequently reported ADR [35]. Aldea-Perona et al. found that all but one 
psychiatric ADRs were related to montelukast in a Spanish database [36]. Psychiatric ADRs were more commonly 
reported in males and children aged 2 to 3 years [36]. Trotta et al. also identified 88 psychiatric ADRs that were 
related to LTMAs in an Italian database [39].  
Regarding the case reports included in the conference abstracts, two cases of hallucination with nervousness and 
one case of sleeping disorders related to montelukast were reported by Burgos et al. [41]. In addition, Erdem et 
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al. identified three cases of seizure possibly induced by LTMAs [43]. All NEs resolved after discontinuation of 
the implicated medication. 
4 Discussion 
To our knowledge, this is the first comprehensive systematic review to investigate the neuropsychiatric safety of 
LTMAs. We include all the literature without restriction to study design or language resulting in a total of 33 
included studies. After summarizing all the evidence, the potential risk of NEs associated with LTMAs cannot be 
ruled out with the preliminary evidence from pharmacovigilance studies, case series, and case reports. However, 
the quality of evidence of these study designs to evaluate such an association is not as high as RCTs and 
observational studies. Of the retrieved articles, only a few observational studies investigating the association 
between NEs and LTMAs were conducted [21-24]. Four published studies did not find an association except one 
conference abstract showing a significant increased risk of depression in patients taking LTMAs [21-24, 38]. 
However, the sample size was comparatively small. The follow-up period and covariates for adjustment were not 
reported in view of the limited information provided in the abstract.  
The null assocaition found in the observational studies may be due to the lack of statistical power to detect the 
rare occurance of suicidal conditions. Still, no significant association was concluded in the post hoc analyses for 
other types of NEs [24]. Of note, a cohort study was published after the submission of this article for peer review 
[44]. A significantly higher risk of medication cessation due to NEs was reported for montelukast when compared 
with ICS. This is in line with the signal of NEs detected form pharmacovigilance studies.      
Although the FDA issued the warning about the association in 2008 [14], there have been controversies over such 
an association [16-20]. Philip et al. conducted an analysis including 46 RCTs published before 2008 and no 
significant association was found (OR 1.12, 95% CI 0.93–1.36) in the review [16]. Notably, the included RCTs 
were not designed to evaluate the association between NEs and LTMAs [14]. As rare outcomes are usually 
difficult to be detected in the comparatively small sample size, the evidence for the result generated from the 
previous review might not be adequate to support the neuropsychiatric safety of LTMAs.  
Post-marketing studies conducted using different global databases demonstrate the potential association. The 
larger databases such as the EV from EU and the Vigibase from the WHO capture reports recorded in the nation-
wide systems which may lead to duplication [8, 10]. As most of them were conducted in different periods with 
different outcomes of interest, these studies were all included in the narrative review to demonstrate the difference 
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in reporting rates. Aldea-Perona et al. conducted a large scale pharmacovigilance study using the Vigibase which 
contained data from 49 countries [10]. The signal detected was further strengthened but a firm conclusion could 
not be drawn due to the limitations of pharmacovigilance studies. Underreporting is common but over-reporting 
can also occur. This is well demonstrated by the significant increase in the reporting rate of NEs after the FDA 
warning was issued in 2008 as indicated in the ITS analysis [26]. Therefore, the detection bias due to the warning 
should be investigated in future drug safety research. 
In addition, covariates cannot be adjusted in pharmacovigilance studies which can lead to confounding bias [10]. 
Some major confounding factors are the severity and comorbidities of asthma. A review from observational 
studies has shown the association between asthma and suicide-related behavior [45]. Asthmatic patients are also 
more likely to have mental health problems including depression and anxiety disorders [46-48]. A lack of control 
of asthma may lead to psychological distress. Therefore, some pharmacovigilance studies included reports of 
ADRs of other asthma medications as comparison groups [6, 8, 11]. Despite the lack of control of confounding, 
using other asthma medications for comparison could provide clinical implications by comparing the rates of 
ADRs among different medications.   
Regarding the study exposure, over half of the studies investigated NEs associated with montelukast only. 
Although other studies aimed to evaluate the whole drug class (LTMAs), it was acknowledged that only a few 
patients were on zafirlukast or zileuton [11, 22]. Consequently, the results were mainly driven by montelukast due 
to its widespread use; and this may lead to a reduction of representativeness of their findings. 
Of note, most of the current studies focused on children only [6-8, 10, 22, 24, 36, 37]. This could be due to the 
widespread use of montelukast among children; and hence, a higher reporting rate of NEs was detected. Notably, 
the age difference was identified by Aldea-Perona et al. as some NEs were more commonly reported in a specific 
age group (sleep disorders in infants aged <2 years; depression or anxiety in children aged 2–11 years; and suicidal 
behavior and depression or anxiety in adolescents aged 12–17 years) [10]. However, evidence on the association 
between NEs and adults is limited. Although NEs resolved after the discontinuation of medications in all case 
reports, the long term effects of NEs on children should be further investigated given the potential association. In 
addition, Bydgell et al. demonstrated the sex difference by showing that aggressiveness was more prevalent in 
boys while sleep disorder and anxiety were more common in girls in the pediatric population aged below 18 years 
[6]. Aldea-Perona et al. also identified a sex difference in two studies in which both reported a higher rate of NEs 
in male than in female [6, 10].   
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Although the association between NEs and LTMAs remains unclear, the possible mechanism of NEs was 
suggested based on animal studies and pharmacological actions of LTMAs. LTMAs mainly act by blocking the 
action of leukotrienes in the respiratory tracts to reduce inflammation [1-3]. Montelukast and zafirlukast are the 
antagonists of cysteinyl leukotriene receptor 1 (CysLT1) while zileuton is a 5-lipoxygenase inhibitor which 
inhibits leukotriene production [1-3]. It was hypothesized that LTMAs block CysLT1 in susceptible pediatric 
patients and cause NEs [49]. Conversely, several animal studies were conducted to investigate the therapeutic 
effect of LTMAs on Alzheimer's disease [50-53]. Leukotriene is involved in the inflammation in the brain and 
CysLT1 is found in the central nervous system [54]. Memory impairment was improved in animal models due to 
the reduction of neuroinflammation, a process potentially related to the progression of Alzheimer's disease [50-
53]. This may contradict the possible theory that NEs are caused by LTMAs; therefore, further studies are required 
to investigate the association as well as the corresponding biological action.  
4.1 Strengths and Limitations 
The inclusion of literature with different study designs and language added strengths to this review. Studies 
investigating different types of NEs associated with any LTMAs were included for a comprehensive review. 
Conference abstracts were also included to reduce publication bias. However, results from conference abstracts 
should be interpreted with caution as they were not subjected to peer-review before publication. Peer-reviewed 
publications remain to be the more robust source of data in this review. Quantification of risks was also not 
conducted due to the lack of RCTs and observational studies investigating the association.  
5 Conclusion 
Many pharmacovigilance studies demonstrate a potential association between NEs and LTMAs. However, RCTs 
and observational studies did not show a statistically significant association. High quality epidemiological studies 
on a larger population should be conducted to evaluate this relationship and quantify the risk of NEs with the use 
of LTMAs, not only in children but also in adults. Although the risk has not been confirmed, the use of LTMAs 
should be evaluated to balance the risks and benefits given the potential NEs of the medications. Clinicians should 
continue to monitor patients for NEs and report ADRs to the appropriate pharmacovigilance organization.  
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